Pioneering the use of machine learning algorithms to turbo-charge drug development
Novel therapy development is expensive, slow, and largely unsuccessful, making it critical to find new ways of bringing medicines to market. MTIP portfolio company, Intelligencia is helping pharmaceuticals and biotech to manage the risk of clinical development and optimize portfolio strategy.
Blog